## Granules India Limited (GRANULES) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Granules India Limited (GRANULES) is a pharmaceutical company listed on the NSE (National Stock Exchange of India) on June 20, 2005.  It operates in the Pharmaceuticals industry, focusing on the manufacturing and supply of pharmaceutical products.  The company's exact positioning within the sector requires further research beyond the provided data, but its presence on the NSE suggests a significant market share within India.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹591            |  Down ₹9.05 (-1.51%) from the previous close.                       |
| Percentage Change (PChange) | -1.51%          | Negative change indicates a downward trend in the current session. |
| Pre-Open Activity          | ₹602.5 (0.41%)  | Positive pre-open activity, but the opening price did not hold.     |
| Week High                    | ₹721 (30-Aug-2024) | Significant high suggests potential for upward movement.           |
| Week Low                     | ₹365.45 (21-Dec-2023) | Significant low indicates considerable volatility.                   |
| VWAP                        | ₹601.03         | Volume Weighted Average Price slightly above the current price.     |
| Sector PE                   | 29.87           | Industry average Price-to-Earnings ratio.                          |
| Symbol PE                   | 29.87           | GRANULES' Price-to-Earnings ratio, in line with the sector average.|
| Delivery Percentage         | 52.61%          | Relatively high delivery percentage suggests some institutional interest.|
| Market Depth                | Low              |  The provided market depth data (total buy/sell quantity = 0) is insufficient for a proper analysis. Further data is needed. |


**3. Financial Performance:**

The provided financial data shows a consistent profit after tax (PAT) and earnings per share (EPS) over the past five quarters, although the figures are unaudited for the most recent two quarters.  However, there's a notable decline in PAT and EPS from Q4 2023 to Q2 2024.

| Quarter      | Revenue (₹) | Expenditure (₹) | PAT (₹)     | EPS (₹) |
|--------------|--------------|-----------------|-------------|---------|
| Q1 2024       | 94,361.6     | 80,710.5        | 9,721.6     | 4.01    |
| Q2 2024       | 85,375.8     | 72,789.9        | 9,377.9     | 3.87    |
| Q3 2024       | 57,077.1     | 51,469.7        | 4,139.2     | 1.71    |
| Q4 2023       | 98,515.1     | 79,353.9        | 14,270.5    | 5.89    |
| Q3 2023       | 101,066.5    | 85,465.2        | 11,615.7    | 4.80    |


**Key Financial Ratios:**  Further analysis requires additional financial statements to calculate key ratios like Return on Equity (ROE), Debt-to-Equity ratio, and others.  The provided data only allows for a superficial assessment.

**4. Corporate Actions and Announcements:**

Granules India has a history of dividend payouts and has conducted a buyback in the past.  Recent announcements include several instances of "Loss of Share Certificates" and updates related to ESOPs, changes in management, and directorial changes.  These announcements, while not directly impacting the stock price significantly in the short term, highlight potential governance issues that need further investigation.  The most recent dividend ex-date was July 30, 2024.

**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|------------|--------------------|-----------|
| 30-Sep-2023  | 41.96                        | 58.04      | 0.00               | 100.00    |
| 31-Dec-2023  | 41.96                        | 58.04      | 0.00               | 100.00    |
| 31-Mar-2024  | 41.96                        | 58.04      | 0.00               | 100.00    |
| 30-Jun-2024  | 38.87                        | 61.13      | 0.00               | 100.00    |
| 30-Sep-2024  | 38.87                        | 61.13      | 0.00               | 100.00    |

A significant decrease in promoter holding from 41.96% to 38.87% between June 2024 and September 2024 is observed. This warrants further investigation into the reasons behind this reduction.

**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the week's high and low prices.  The CM Annual Volatility of 48.14% further confirms this.  The risk-reward profile is currently skewed towards higher risk due to this volatility and the recent decline in financial performance.  The lack of sufficient market depth data hinders a more precise risk assessment.

**7. Advantages of Buying the Stock:**

* Consistent dividend payouts (historical data).
* Presence in a growing pharmaceutical sector.


**8. Disadvantages and Risks:**

* High volatility.
* Recent decline in PAT and EPS.
* Decrease in promoter holding.
* Insufficient market depth data.
* Several announcements regarding loss of share certificates and management changes raise governance concerns.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Don't Buy.** The recent price decline and high volatility make a short-term investment risky.  The lack of strong short-term triggers further supports this recommendation.

* **Medium-term (3 to 12 months): Hold (if you have stock), Don't Buy (if you don't).**  The medium-term outlook depends on the company's ability to reverse the recent decline in financial performance and address the governance concerns.  Further investigation into the reasons behind the decrease in promoter holding is crucial.

* **Long-term (1 year and beyond): Hold (if you have stock), Don't Buy (if you don't).**  Long-term investment requires a thorough fundamental analysis, including a detailed examination of the company's competitive advantages, management quality, and future growth prospects.  The current data is insufficient to make a strong buy recommendation for the long term.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 5.5**

* Financial Health (out of 10): 6 (Consistent profitability in the past, but recent decline is concerning).
* Market Performance (out of 10): 4 (High volatility, recent price decline).
* Volatility and Risk (out of 10): 3 (High volatility, insufficient market depth data).
* Corporate Actions & Governance (out of 10): 4 (Consistent dividends, but governance concerns raised by announcements).
* Shareholding Patterns (out of 10): 5 (Significant decrease in promoter holding needs further investigation).

**Analysis Score (out of 10): 7**

* Completeness and Utilization of Data (out of 10): 8 (Most data points were used, but some crucial information was missing).
* Accuracy and Clarity of Analysis (out of 10): 7 (Analysis is clear, but some conclusions are tentative due to data limitations).
* Professional Formatting (out of 10): 8 (Report is well-structured and easy to read).


**11. Professional Recommendation Summary:**

Based on the available data, GRANULES presents a mixed picture. While it has a history of dividend payouts and operates in a growing sector, recent financial performance has declined, and volatility is high.  The decrease in promoter holding and several announcements raise governance concerns.  Therefore, a "Don't Buy" recommendation is given for short-term and long-term investment horizons.  For medium-term investors who already hold the stock, a "Hold" recommendation is given, contingent upon further investigation into the company's performance and governance issues.  A more comprehensive analysis with additional data is recommended before making any investment decisions.
